Compare CWBC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWBC | ARVN |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.6M | 600.2M |
| IPO Year | 2000 | 2018 |
| Metric | CWBC | ARVN |
|---|---|---|
| Price | $26.04 | $7.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $29.70 | $13.93 |
| AVG Volume (30 Days) | 165.4K | ★ 646.8K |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | ★ 344.44 | 58.84 |
| EPS | 0.61 | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $41.04 | $12.76 |
| Revenue Next Year | $13.98 | N/A |
| P/E Ratio | $42.98 | ★ $4.54 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.70 | $6.74 |
| 52 Week High | $28.17 | $14.22 |
| Indicator | CWBC | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 43.63 |
| Support Level | $25.05 | $6.74 |
| Resistance Level | $26.43 | $7.74 |
| Average True Range (ATR) | 0.68 | 0.36 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 51.08 | 51.43 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments. The company has one reportable segment: Banking operations. Loans and leases, investment securities, interest-bearing deposits and non-interest income provide the revenues of the banking operation.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.